GL1X · GenesisL1 explorer

MolNFT v1 · #126604 · protein

Structure of human O-glcnac hydrolase with new iminocyclitol type inhibitor

5M7U · Protein O-glcnacase: “Structure of human O-glcnac hydrolase with new iminocyclitol type inhibitor”. X-ray diffraction, 1 ligand (XHA), 6 pockets (best druggability 0.79). MolNFT v1 #126604 on GenesisL1: 3D structure, binding sites…

PDB
5M7U
Type
protein
Length
896 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protein O-glcnacase
EC
3.2.1.169, 3.2.1.-
UniProt
O60502
Ligands
XHA
Pockets
6 · best druggability 0.79

Structure

x-ray diffraction · 2 distinct chains · 49% helix, 9% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProtein O-glcnacase (EC 3.2.1.169, 3.2.1.-)protein44849% helix, 9% strandO60502
BProtein O-glcnacase (EC 3.2.1.169, 3.2.1.-)protein44849% helix, 9% strandO60502

Ligands and binding sites

  • XHA · 2-[(2~{R},3~{S},4~{R},5~{R})-5-(hydroxymethyl)-3,4-bis(oxidanyl)-1-[3-[3-(trifluoromethyl) phenyl]propyl]pyrrolidin-2-yl]-~{N}-methyl-ethanamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111000.790.8186empty
25810.690.7876XHA
34120.640.7853XHA
4690.610.9116empty
5510.290.7611empty

Interfaces

1 interface between chains.

  • A–B · 4515 Ų buried · 43 hydrogen bonds · protein-protein

Compared structures

  • 5M7U · Structure of human O-GlcNAc hydrolase with new iminocyclitol type inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • O60502 · AlphaFold monomer V2.0 prediction for protein O-glcnacase (O60502) · a predicted model of the same protein · chain B against A, TM-score 0.94

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.